4-amino-cis-2-buten-1-ol | 89211-20-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-amino-cis-2-buten-1-ol
• 英文别名: cis-4-hydroxy-2-butenylamine；4-amino-2-buten-1-ol；4-Aminobut-2-EN-1-OL；(E)-4-aminobut-2-en-1-ol
• CAS: 89211-20-1
• 化学式: C₄H₉NO
• 分子量: 87.1216
• InChiKey: VVBVTZZZFFHHSP-OWOJBTEDSA-N

物化性质

• 沸点：
  84-85 °C(Press: 1.5 Torr)
• 密度：
  1.011 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P210,P261,P280,P305+P351+P338
• 危险性描述：
  H227,H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-amino-cis-2-buten-1-ol 、 (R)-3-tert-butoxycarbonyl-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以74%的产率得到(R)-N-(cis-4-hydroxy-2-buten-1-yl)-3-tert-butoxycarbonyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Small-Sized Human Immunodeficiency Virus Type-1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S₂′ Pocket

  摘要：

  A series of HIV protease inhibitor based on the allophenylnorstatine structure with various P-2' moieties were synthesized. Among these analogues, we discovered that a small allyl group would maintain potent enzyme inhibitory activity compared to the o-methylbenzyl moiety in clinical candidate I (KNI-764, also known as JE-2147, AG-1776, or SM-319777). Introduction of all anilinic amino group to 2 (KNI-727) improved water-solubility and anti-HIV-1 activity, X-ray crystallographic analysis of 13k (KNI-1689) with a beta-methallyl group kit P-2' position revealed hydrophobic interactions with Ala28, Ile84, kind Ile50' similar to that of 1. The presence of an additional methyl group on the allyl group in compound 13k significantly increased anti-HIV activity over 1 while providing a rational drug design for structural minimization and improving membrane permeability.

  DOI：

  10.1021/jm9005115

文献信息

• 4-aminomethyl-pyridyl-2-oxy derivatives having anti-ulcer activity
  申请人：Fujirebio Kabushiki Kaisha

  公开号：US04912101A1

  公开（公告）日：1990-03-27

  A compound represented by the following formula or a salt thereof ##STR1## wherein each of R.sub.1 and R.sub.2 represents a lower alkyl group, or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, may form a substituted or unsubstituted, saturated or partially unsaturated 4- to 8-membered heterocyclic group which may contain a hetero atom selected from N, O and S, Y represents a group of the formula --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2. This compound is useful as anti-peptic ulcer agent.

  该化合物由以下式表示，或其盐##STR1##其中R.sub.1和R.sub.2中的每一个代表较低的烷基基团，或者R.sub.1和R.sub.2，与它们结合的氮原子一起，可以形成一个取代或未取代、饱和或部分不饱和的4-至8-成员杂环基团，该基团可能包含从N、O和S中选择的杂原子，Y代表式--CH.sub.2 --CH.sub.2 --或--CH.dbd.CH--的基团，n为0、1或2。该化合物可用作抗溃疡药。
• NOHARA, FUJIO;FUJINAWA, TOMOAKI
  作者：NOHARA, FUJIO、FUJINAWA, TOMOAKI

  DOI：——

  日期：——
• ——
  作者：HOXAPA FUDZIO、 FUDZINAVA TOMOAKI

  DOI：——

  日期：——
• Small-Sized Human Immunodeficiency Virus Type-1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S₂′ Pocket
  作者：Koushi Hidaka、Tooru Kimura、Hamdy M. Abdel-Rahman、Jeffrey-Tri Nguyen、Keith F. McDaniel、William E. Kohlbrenner、Akhteruzzaman Molla、Motoyasu Adachi、Taro Tamada、Ryota Kuroki、Noriko Katsuki、Yoshiaki Tanaka、Hikaru Matsumoto、Jun Wang、Yoshio Hayashi、Dale J. Kempf、Yoshiaki Kiso

  DOI：10.1021/jm9005115

  日期：2009.12.10

  A series of HIV protease inhibitor based on the allophenylnorstatine structure with various P-2' moieties were synthesized. Among these analogues, we discovered that a small allyl group would maintain potent enzyme inhibitory activity compared to the o-methylbenzyl moiety in clinical candidate I (KNI-764, also known as JE-2147, AG-1776, or SM-319777). Introduction of all anilinic amino group to 2 (KNI-727) improved water-solubility and anti-HIV-1 activity, X-ray crystallographic analysis of 13k (KNI-1689) with a beta-methallyl group kit P-2' position revealed hydrophobic interactions with Ala28, Ile84, kind Ile50' similar to that of 1. The presence of an additional methyl group on the allyl group in compound 13k significantly increased anti-HIV activity over 1 while providing a rational drug design for structural minimization and improving membrane permeability.